Mark Hillman's Portfolio Shows Mixed Quarterly Activity
Mark Hillman's Hillman Value Fund portfolio, valued at approximately $144 million as of March 31, 2026, displayed significant changes in holdings across various sectors, with notable increases in CARMAX and DUPONT, decreases in Warner Bros Discovery and others, and relatively stable positions.
As of March 31, 2026, Mark A. Hillman's Hillman Value Fund portfolio held a total value of approximately $144 million. The portfolio's top holdings, representing significant allocations, showed varied changes in share counts during the most recent quarter.
Investment in CARMAX INC (KMX) saw a substantial increase, with shares rising by 19.34% (an increase of 17,692 shares). Similarly, DUPONT DE NEMOURS INC (DD) experienced a significant rise, with shares increasing by 65.65% (an increase of 46,727 shares).
Conversely, Warner BROS DISCOVERY INC (WBD) witnessed a substantial decrease, with shares falling by 40.64% (a reduction of 134,418 shares). Other stocks showing significant declines included GSK PLC (GSK) (-31.28%), BIOGEN INC (BIIB) (-22.98%), PFEZER INC (PFE) (-13.21%), and CVS HEALTH CORP (CVS) (-18.09%).
Several holdings maintained relatively stable share counts during the quarter, including INTERNATIONAL FLAVORS&FRAGRA (IFF) (-8.19%), BROWN FORMAN CORP (BF-B) (-6.28%), ZIMMER BIOMET HOLDINGS INC (ZBH) (+5.46%), and BF-B (-6.28%).
For a detailed view of Mark Hillman's investment profile, visit Mark Hillman's profile. You can explore the performance of specific stocks like BIOGEN INC (BIIB), DUPONT DE NEMOURS INC (DD), and CARMAX INC (KMX) on Insiderset.